Clonazepam (Psy and Mixed indications) updated on 02-10-2025

Low birth weight (< 2500g)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17718
R74731
Christensen (Indications other than epilepsy), 2024 Low birth weight (<2500 g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes BZD Coexposure: No (among antiseizure medications) Indication BZD: Psychiatric diseases (depression, anxiety, ...) 0.96 [0.73;1.28] 59/1,019   140,436/4,445,621 140,495 1,019
ref
S15674
R64713
Coste (Indications other than epilepsy), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No BZD Coexposure: No (among antiseizure medications) 1.63 [1.33;1.99] C 105/1,246   91,455/1,710,441 91,560 1,246
ref
Total 2 studies 1.26 [0.75;2.12] 232,055 2,265
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Christensen (Indications other than epilepsy), 2024Christensen, 2024 1 0.96[0.73; 1.28]140,4951,01948%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Coste (Indications other than epilepsy), 2020Coste, 2020 2 1.63[1.33; 1.99]91,5601,24652%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 89% 1.26[0.75; 2.12]232,0552,2650.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Indications other than epilepsy; 2: Indications other than epilepsy;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.26[0.75; 2.12]232,0552,26589%NAChristensen (Indications other than epilepsy), 2024 Coste (Indications other than epilepsy), 2020 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.26[0.75; 2.12]232,0552,26589%NAChristensen (Indications other than epilepsy), 2024 Coste (Indications other than epilepsy), 2020 2 Tags Adjustment   - No  - No 1.63[1.33; 1.99]91,5601,246 -NACoste (Indications other than epilepsy), 2020 1   - Yes  - Yes 0.96[0.72; 1.27]140,4951,019 -NAChristensen (Indications other than epilepsy), 2024 1 BZD Coexposure   - No (among antiseizure medications)  - No (among antiseizure medications) 1.26[0.75; 2.12]232,0552,26589%NAChristensen (Indications other than epilepsy), 2024 Coste (Indications other than epilepsy), 2020 2 Indication BZD   - Psychiatric diseases (depression, a ...  - Psychiatric diseases (depression, anxiety, ...) 0.96[0.72; 1.27]140,4951,019 -NAChristensen (Indications other than epilepsy), 2024 1 All studiesAll studies 1.26[0.75; 2.12]232,0552,26589%NAChristensen (Indications other than epilepsy), 2024 Coste (Indications other than epilepsy), 2020 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.26[0.75; 2.12]232,0552,26589%NAChristensen (Indications other than epilepsy), 2024 Coste (Indications other than epilepsy), 2020 20.510.01.0